FFPE tissue sections (4-μm thick) were prepared. Antigen retrieval was performed using the
Epitope Retrieval Solution pH 9 (Leica Biosystems, Wetzlar, Germany). To block endogenous peroxidase activity, the sections were incubated in a 0.3% H
2O
2 solution in methanol. Ten percent goat serum (Nichirei Bioscience, Tokyo, Japan) was used to block the sections. The primary antibodies used were HPV-L1 antibody (K1H8) (Thermo Fisher Scientific, Waltham, MA, USA), p16 (E4H6) (Roche, Basel, Switzerland), and
Ki-67 (MIB-1) (DAKO, Santa Clara, CA, USA). HPV type 6 E4 and type 11 E4 antibodies, as described previously, were also used
21 (link). For secondary antibodies, a MAX-PO(M) or MAX-PO(R) kit (Nichirei Bioscience, Tokyo, Japan) was used. The sections were visualised with DAB.
L1 and E4 double staining was performed by L1 and visualised by DAB, and E4 was visualised using the
ImmPACT Vector Red AP Substrate Kit (Vector Laboratories, Newark, CA, USA).
IHC evaluations were performed independently by two pathologists who were blinded to patient information. IHC was evaluated as positive or negative for L1 and E4, the MIB-1 index was calculated as percentage of Ki-67 IHC-positive cells/total tumour cells, and p16 was calculated as the immunoreactive score (IRS) using staining intensity as percentage of the positive tumour cells (Suppl. Fig.
S2)
37 (link).
Yamada S., Itoh T., Ikegami T., Imai A., Mochizuki D., Nakanishi H., Ishikawa R., Kita J., Nakamura Y., Takizawa Y., Okamura J., Noda Y., Iwashita T., Hariyama T., Suzuki M., Misawa K, & Kawasaki H. (2023). Association between human papillomavirus particle production and the severity of recurrent respiratory papillomatosis. Scientific Reports, 13, 5514.